Skip to main content

Table 2 Prognostic factors in patients with metastatic HCC

From: Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience

Parameters

Univariate

Multivariate

HR1

95% CI2

p

HR

95% CI

p

Age

0.99

0.98 - 1.01

0.745

   

gender (male vs. female)

1.43

0.96 - 2.14

0.082

   

Intrahepatic tumor expansion (multifocal vs. oligonodular)

1.74

1.23 - 2.47

0.002

1.63

1.11 - 2.42

0.014

Tumor size (cm)

1.00

0.97 - 1.04

0.889

   

ECOG

  

0.127

   

 0

1

     

 1

1.04

0.69-1.58

    

 2

1.50

1.01-2.22

    

Treatment

  

<0.001

  

0.007

 No therapy

1

  

1

  

 Sorafenib

0.62

0.43 – 0.91

0.013

0.86

0.56 – 2.26

0.475

 TACE

0.45

0.30 – 0.66

<0.001

0.54

0.35 – 0.84

0.006

 TACE and sorafenib

0.41

0.25 – 0.68

<0.001

0.48

0.28 – 0.81

0.006

ALBI

  

<0.001

  

<0.001

 ALBI 1

1

  

1

  

 ALBI 2

1.63

1.15 - 2.31

0.006

1.56

1.10 - 2.30

0.026

 ALBI 3

3.33

2.15 - 5.15

<0.001

3.42

2.09 - 5.61

<0.001

viral vs. non-viral etiology

0.89

0.65 - 1.20

0.432

   

Segmental portal vein thrombosis

1.12

0.97 - 1.29

0.128

   

AFP > 400 ng/ml

1.51

1.13 - 2.01

0.005

1.50

1.10 - 1.92

0.010

BCLC (C vs. D)

5.15

3.31 - 8.02

<0.001

2.45

1.42 – 4.29

0.001

multiple metastases

0.96

0.69 - 1.33

0.797

   
  1. TACE is an independent prognostic factor in patients with metastatic HCC. Moreover, liver function represented by the ALBI score is also a strong prognostic factor indicating the importance of a preserved liver function for OS in these patients
  2. Abbreviations: 1 HR hazard ratio, 2 95% CI 95% confidence interval